Few options are available for treating patients with advanced
prostate cancer (PC). As PC is a slow growing disease and accessible by ultrasound, gene therapy could provide a viable option for this
neoplasm. Conditionally replication-competent adenoviruses (CRCAs) represent potentially useful
reagents for treating PC. We previously constructed a CRCA,
cancer terminator virus (CTV), which showed efficacy both in vitro and in vivo for PC. The CTV was generated on a serotype 5-background (Ad.5-CTV) with infectivity depending on Coxsackie-
Adenovirus Receptors (CARs). CARs are frequently reduced in many
tumor types, including PCs thereby limiting effective Ad-mediated
therapy. Using serotype chimerism, a novel CTV (
Ad.5/3-CTV) was created by replacing the
Ad.5 fiber knob with the Ad.3 fiber knob thereby facilitating
infection in a CAR-independent manner. We evaluated
Ad.5/3-CTV in comparison with Ad.5-CTV in low CAR human PC cells, demonstrating higher efficiency in inhibiting cell viability in vitro. Moreover,
Ad.5/3-CTV potently suppressed in vivo
tumor growth in a nude mouse xenograft model and in a spontaneously induced PC that develops in Hi-myc transgenic mice. Considering the significant responses in a Phase I clinical trial of a non-replicating Ad.5-mda-7 in advanced
cancers,
Ad.5/3-CTV may exert improved therapeutic benefit in a clinical setting.